Is quantitative oestrogen receptor expression useful in the evaluation of the clinical prognosis? Analysis of a homogeneous series of 797 patients with prospective determination of the ER status using simultaneous EIA and IHC

European Journal of Cancer

Volumn 46, Issue 15, 2010, Pages 2716-2725

  Mazouni, Chafika ^a,b   Bonnier, Pascal ^c   Goubar, Aïcha ^d   Romain, Sylvie ^b   Martin, Pierre Marie ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Laboratoire de Transfert Biologique Oncologique   (France)

^c Clinique Beauregard   (France)

^d IGR   (France)

Author keywords

Breast cancer; Enzyme immunoassay; Hormonal treatment; Immunohistochemistry; Oestrogen receptor; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; DISEASE FREE SURVIVAL; ENZYME IMMUNOASSAY; EVALUATION; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77957205395     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.05.021     Document Type: Article

References (39)

1. A. Goldhirsch, J.N. Ingle, and R.D. Gelber Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 2009 1319 1329
2. A. Goldhirsch, J.H. Glick, and R.D. Gelber Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005 Ann Oncol 16 2005 1569 1583 (Pubitemid 41511089)
3. F. Rastelli, and S. Crispino Factors predictive of response to hormone therapy in breast cancer Tumori 94 2008 370 383
4. S. Romain, J.L. Formento, and O. Guirou Determination of oestrogen receptors by enzyme immunoassay. Technical differences between laboratories and their consequences Eur J Cancer 30 1994 740 746 (Pubitemid 24217326)
5. S. Romain, O. Chinot, O. Guirou, M. Soullire, and P.M. Martin Biological heterogeneity of ER-positive breast cancers in the post-menopausal population Int J Cancer 59 1994 17 19 (Pubitemid 24310941)
6. Y. Gong, K. Yan, and F. Lin Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study Lancet Oncol 8 2007 203 211 (Pubitemid 46304454)
7. R.C. Bast Jr., P. Ravdin, and D.F. Hayes 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology J Clin Oncol 19 2001 1865 1878 (Pubitemid 32230890)
8. A. Goldhirsch, W.C. Wood, and R.D. Gelber Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer J Clin Oncol 21 2003 3357 3365 (Pubitemid 46606270)
9. D.A. Turbin, S. Leung, and M.C. Cheang Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases Breast Cancer Res Treat 110 2008 417 426 (Pubitemid 351962583)
10. M. Dowsett, C. Allred, and J. Knox Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial J Clin Oncol 26 2008 1059 1065
11. F. Andre, K. Broglio, and H. Roche Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis J Clin Oncol 26 2008 2636 2643
12. N. Magné, R.A. Toillon, P. Castadot, A. Ramaioli, and M. Namer Different clinical impact of estradiol receptor determination according to the analytical method: a study on 1940 breast cancer patients over a period of 16 consecutive years Breast Cancer Res Treat 95 2006 179 184
13. W.L. McGuire Steroid hormone receptors in breast cancer treatment strategy Recent Prog Horm Res 36 1980 135 156
14. J.C. Heuson, W.H. Mattheiem, E. Longeval, M.C. Deboel, and G. Leclercq Clinical significance of the quantitative assessment of estrogen receptors in breast cancer Hormones and breast cancer 1976 INSERM Paris 57 70
15. P. Bonnier, S. Romain, and P.L. Giacalone Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy Obstet Gynecol 85 1995 11 17
16. C.G. Sweep, and J. Geurts-Moespot EORTC external quality assurance program for ER and PgR measurements: trial 1998/1999. European Organisation for Research and Treatment of Cancer Int J Biol Markers 15 2000 62 69
17. M.A. Blankenstein Comparison of ligand binding assay and enzyme immunoassay of oestrogen receptor in human breast cancer cytosols. Experience of the E.O.R.T.C. receptor group Breast Cancer Res Treat. 17 1990 91 98
18. S.M. Thorpe, I.J. Christensen, B.B. Rasmussen, and C. Rose Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer Eur J Cancer 29A 1993 971 977 (Pubitemid 23126694)
19. S. Desruisseau, J. Palmari, and C. Giusti Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival Br J Cancer 94 2006 239 246 (Pubitemid 43151542)
20. M. Bonetti, and R.D. Gelber A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data Stat Med 19 2000 2595 2609
21. M. Bonetti, and R.D. Gelber Patterns of treatment effects in subsets of patients in clinical trials Biostatistics 5 2004 465 481 (Pubitemid 41180219)
22. S. Romain, F. Spyratos, J. Goussard, J.L. Formento, and H. Magdalénat Improvement of quality control for steroid receptor measurements: analysis of distributions in more than 40000 primary breast cancers. French Study Group on Tissue and Molecular Biopathology Breast Cancer Res Treat 41 1996 131 139
23. D.C. Allred Problems and solutions in the evaluation of hormone receptors in breast cancer J Clin Oncol 26 2008 2433 2435
24. D.C. Allred Commentary: hormone receptor testing in breast cancer: a distress signal from Canada Oncologist 13 2008 1134 1136
25. G. Viale, M.M. Regan, and E. Maiorano Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98 J Clin Oncol 25 2007 3846 3852 (Pubitemid 47477259)
26. P. Roepman, H.M. Horlings, and O. Krijgsman Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer Clin Cancer Res 15 2009 7003 7011
27. A. Merglen, H.M. Verkooijen, and G. Fioretta Hormonal therapy for oestrogen receptor-negative breast cancer is associated with higher disease-specific mortality Ann Oncol 20 2009 857 861
28. P.M. Martin, S. Romain, and F. Spyratos Reevaluation of indications for adjuvant hormone therapy in primary breast cancer with high metastatic risk Bull Cancer 78 1991 709 723
29. B. Thürlimann, K.N. Price, and R.D. Gelber Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93 Breast Cancer Res Treat 113 2009 137 144
30. O. Pagani, S. Gelber, and E. Simoncini Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93 Breast Cancer Res Treat 116 2009 491 500
31. International Breast Cancer Study Group (IBCSG), Castiglione-Gertsch M, O'Neill A, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2003;95:1833-46. (Pubitemid 38054684)
32. A. Reiner, B. Neumeister, and J. Spona Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer Cancer Res 50 1990 7057 7061 (Pubitemid 20361113)
33. W. Remmele, and K.H. Schicketanz Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS) Pathol Res Pract 189 1993 862 866 (Pubitemid 23308006)
34. D.C. Allred, J.M. Harvey, M. Berardo, and G.M. Clark Prognostic and predictive factors in breast cancer by immunohistochemical analysis Mod Pathol 11 1998 155 168 (Pubitemid 28144151)
35. J.M. Harvey, G.M. Clark, C.K. Osborne, and D.C. Allred Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 1999 1474 1481
36. P. Regitnig, A. Reiner, and H.P. Dinges Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories Virchows Arch 441 2002 328 334 (Pubitemid 36015595)
37. K. Arihiro, S. Umemura, and M. Kurosumi Comparison of evaluations for hormone receptors in breast carcinoma using two manual and three automated immunohistochemical assays Am J Clin Pathol 127 2007 356 365 (Pubitemid 46806328)
38. K. Albain, W. Barlow, and F. O'Malley Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, estrogen (ER) and/or progesterone (PR) receptor-positive breast cancer: Mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814) Breast Cancer Res Treat 88 2004 S20 [abstr 37]
39. S. Umemura, J. Itoh, and H. Itoh Immunohistochemical evaluation of hormone receptors in breast cancer: which scoring system is suitable for highly sensitive procedures? Appl Immunohistochem Mol Morphol 12 2004 8 13 (Pubitemid 38332312)